Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

Optimal bone health management strategies in patients with prostate cancer.

Prakash G, Gautam G.

Indian J Urol. 2013 Apr;29(2):89-99. doi: 10.4103/0970-1591.114024.

PMID:
23956508
[PubMed]
Free PMC Article
2.

Bone health and prostate cancer.

Saylor PJ, Smith MR.

Prostate Cancer Prostatic Dis. 2010 Mar;13(1):20-7. doi: 10.1038/pcan.2009.50. Epub 2009 Nov 10. Review.

PMID:
19901958
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Emerging therapies to prevent skeletal morbidity in men with prostate cancer.

Saylor PJ, Lee RJ, Smith MR.

J Clin Oncol. 2011 Sep 20;29(27):3705-14. doi: 10.1200/JCO.2010.34.4994. Epub 2011 Aug 22. Review.

PMID:
21860001
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Management of bone metastases in refractory prostate cancer--role of denosumab.

Paller CJ, Carducci MA, Philips GK.

Clin Interv Aging. 2012;7:363-72. doi: 10.2147/CIA.S27930. Epub 2012 Sep 17. Review.

PMID:
23049248
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.

Higano CS.

Urol Clin North Am. 2004 May;31(2):331-52. Review.

PMID:
15123412
[PubMed - indexed for MEDLINE]
6.

Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.

Saylor PJ.

Asian J Androl. 2014 May-Jun;16(3):341-7. doi: 10.4103/1008-682X.122591.

PMID:
24435057
[PubMed - in process]
Free PMC Article
7.

[The clinical merit of anti-RANKL antibody denosumab in prostate cancer].

Akaza H, Tsukamoto T, Suzuki K, Namiki M, Ozono S, Naitodept S.

Gan To Kagaku Ryoho. 2012 Feb;39(2):207-12. Japanese.

PMID:
22333629
[PubMed - indexed for MEDLINE]
8.

Contemporary therapeutic approaches targeting bone complications in prostate cancer.

Lee RJ, Saylor PJ, Smith MR.

Clin Genitourin Cancer. 2010 Dec 1;8(1):29-36. doi: 10.3816/CGC.2010.n.005. Review.

PMID:
21208853
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.

Saad F, McKiernan J, Eastham J.

Urol Oncol. 2006 Jan-Feb;24(1):4-12. Review.

PMID:
16414486
[PubMed - indexed for MEDLINE]
10.

Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.

Smith MR.

Urol Oncol. 2008 Jul-Aug;26(4):420-5. doi: 10.1016/j.urolonc.2007.11.004. Review.

PMID:
18593621
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

J Manag Care Pharm. 2011 Oct;17(8):621-43.

PMID:
21942303
[PubMed - indexed for MEDLINE]
Free Article
12.

The role of osteoclastic activity in prostate cancer skeletal metastases.

Keller ET.

Drugs Today (Barc). 2002 Feb;38(2):91-102. Review.

PMID:
12532187
[PubMed - indexed for MEDLINE]
13.

Managing bone metastases and reducing skeletal related events in prostate cancer.

Gartrell BA, Saad F.

Nat Rev Clin Oncol. 2014 Jun;11(6):335-45. doi: 10.1038/nrclinonc.2014.70. Epub 2014 May 13.

PMID:
24821212
[PubMed - in process]
14.

Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.

Saad F, Olsson C, Schulman CC.

Eur Urol. 2004 Dec;46(6):731-39; discussion 739-40. Review.

PMID:
15548440
[PubMed - indexed for MEDLINE]
15.

Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.

Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB.

Pharmacotherapy. 2012 Mar;32(3):274-84. doi: 10.1002/j.1875-9114.2011.01092.x. Epub 2012 Feb 13. Review.

PMID:
22392458
[PubMed - indexed for MEDLINE]
16.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD003474. doi: 10.1002/14651858.CD003474.pub3. Review.

PMID:
22336790
[PubMed - indexed for MEDLINE]
17.

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.

Brown-Glaberman U, Stopeck AT.

Biologics. 2012;6:89-99. doi: 10.2147/BTT.S20677. Epub 2012 Apr 12.

PMID:
22532777
[PubMed]
Free PMC Article
18.

Osteoclast-targeted therapy for prostate cancer.

Smith MR.

Curr Treat Options Oncol. 2004 Oct;5(5):367-75. Review.

PMID:
15341675
[PubMed - indexed for MEDLINE]
19.

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD.

Eur Urol. 2014 Feb;65(2):278-86. doi: 10.1016/j.eururo.2013.05.015. Epub 2013 May 13.

PMID:
23706567
[PubMed - in process]
20.

Bone health in men with prostate cancer: diagnostic and therapeutic considerations.

Saad F, Perrotte P, Bénard F, McCormack M, Karakiewicz PI.

Can J Urol. 2005 Jun;12 Suppl 2:9-15. Review.

PMID:
16018826
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk